Iotrex

Iotrex

Radiation oncology A radioisotope solution used for brachytherapy. See Brachytherapy.
Mentioned in ?
References in periodicals archive ?
IsoRay owns exclusive worldwide distribution rights for GliaSite and exclusive worldwide licensing rights to Iotrex, a liquid iodine radiation for brain cancer treatment.
Iotrex delivers radiation to the edges of the tumor cavity, targeting tissue where cancer may remain.
With the FDA clearance, IsoRay will now be able to move forward in seeking additional regulatory approval for its new liquid form of Cesium-131 internal radiation therapy for the treatment of brain cancer that would be delivered using the GliaSite[R] system replacing Iotrex.
IsoRay is in the final stage of testing its GliaSite catheter system with Iotrex for submission of its 510K for GliaSite to the FDA.
Use of Iotrex opens an immediate market opportunity to generate revenues from sales of GliaSite[R] in the brain cancer market, while IsoRay seeks final approval for liquid Cesium-131 for use in the GliaSite[R] therapy system.
The establishment of special payment for Iotrex broadens reimbursement for GliaSite and should allow more Medicare beneficiaries to receive outpatient treatment.